Health, Imaging, and Cognition Across the Menopausal Transition
NCT07021664, Recruiting, Université de Sherbrooke
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Health, Imaging, and Cognition Across the Menopausal Transition | ClinicalTrials.gov |
| NCT number | NCT07021664 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Enrollment | 45 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Université de Sherbrooke | ClinicalTrials.gov |
| Conditions | Menopause | ClinicalTrials.gov |
| First posted | 2025-06-15 | ClinicalTrials.gov |
| Last updated | 2026-10-26 | ClinicalTrials.gov |
Registered outcomes 29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | cerebral metabolic rates (μmol/100 g/min) measured by PET (11C-AcAc +18F-FDG) | 1 day at baseline | Brain energy metabolism will be quantified using two PET tracers: 11C-acetoacetate (for ketone use) and 18F-fluorodeoxyglucose (for glucose use). This will allow comparison of brain fuel usage between three menopausal groups (PRE, PERI, POST).Total Cerebral metabolic rates (μmol/100 g/min) (CMR tot= CMR acac + CMRglu) | ClinicalTrials.gov |
| Primary | Tracer influx rates (k) measured by PET (11C-AcAc +18F-FDG) | 1 day at baseline | Brain energy metabolism will be quantified using two PET tracers: 11C-acetoacetate (for ketone use) and 18F-fluorodeoxyglucose (for glucose use). This will allow comparison of brain fuel usage between three menopausal groups (PRE, PERI, POST). tracer influx rates (K values). | ClinicalTrials.gov |
| Secondary | Time-activity curves of the estrogen receptor in the brain (by 18F-4FMFES PET) | 1 day at baseline | Time-activity curves of the estrogen recept will be measured using 18F-4FMFES PET express as SUV (Standardized Uptake Value) | ClinicalTrials.gov |
| Secondary | distribution volume ratio of the estrogen receptor in the brain (by 18F-4FMFES PET) | 1 day at baseline | distribution volume ratio of the estrogen receptor will be measured by kinetic modelisation using 18F-4FMFES PET. | ClinicalTrials.gov |
| Secondary | Glucose variability (SD of glucose measured by continuous glucose monitoring) | Over 5 days following sensor placement et stabilisation | Continuous glucose monitoring (CGM) will track glucose levels over several days. Glycemic variability will be assessed by the standard deviation of glucose values over the 5 days monitoring period. (mmol/L) | ClinicalTrials.gov |
| Secondary | Glucose average (mean of glucose measured by continuous glucose monitoring) | Over 5 days following sensor placement et stabilisation | Continuous glucose monitoring (CGM) will track glucose levels over several days. Average glucose concentration over the monitoring period.(mmol/L) | ClinicalTrials.gov |
| Secondary | Time in range | Over 5 days following sensor placement et stabilisation | Total minutes with glucose values within the standard glycemic range (3.9-10.0 mmol/L) over the 5 days monitoring period. (min) | ClinicalTrials.gov |
| Other | Brain volume | 1 day at baseline | Will be measured by MRI - T1-weighted images and express in cm³ | ClinicalTrials.gov |
| Other | Rey Auditory Verbal Learning Test (RAVLT) | 1 day at baseline | Assesses verbal memory. Total score (range: 0-75); higher scores indicate better performance | ClinicalTrials.gov |
| Other | Stroop Color and Word test (Stroop Test) (secondes) | 1 day at baseline | Measures processing speed and executive function; outcome is time to completion. Unit of Measure: Seconds; lower scores indicate better performance | ClinicalTrials.gov |
| Other | Trail making test (secondes) | 1 day at baseline | Assesses cognitive flexibility, visual attention, and processing speed. Unit of Measure: Seconds; lower scores indicate better performance | ClinicalTrials.gov |
| Other | Montreal Cognitive Assessment (MoCA) score | 1 day at baseline | Global cognitive screening tool. Unit of Measure: Score (range: 0-30); higher scores indicate better cognition. | ClinicalTrials.gov |
| Other | Boston naming tests (total answer) | 1 day at baseline | Measures language and word retrieval ability.Total correct responses (range: 0-60); higher scores are better | ClinicalTrials.gov |
| Other | Symbol coding (score) | 1 day at baseline | Assesses processing speed.Score (higher = better) | ClinicalTrials.gov |
| Other | Logical Memory Subtest of the Wechsler Memory Scale-IV | 1 day at baseline | Assesses elayed story recall. Score (0-25); higher scores indicate better memory | ClinicalTrials.gov |
| Other | Fasting plasma glucose (mM) | 1 day at baseline | Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups | ClinicalTrials.gov |
| Other | Fasting plasma insulin (mM) | 1 day at baseline | Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups | ClinicalTrials.gov |
| Other | Fasting plasma HbA1c (%) | 1 day at baseline | Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups | ClinicalTrials.gov |
| Other | Fasting plasma total ketone (uM) | 1 day at baseline | Blood samples will be used to assess the systemic metabolis plasma markers and will be compared across 3 groups. Total ketone = acetoacetate + beta-hydroxybutyrate | ClinicalTrials.gov |
| Other | Estrogene levels (pmol/L) | 1 day at baseline | Blood samples will be used to assess sex hormone and will be compared across 3 group | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 17
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 10981461 | BACKGROUND | PubMed |
| 22344196 | BACKGROUND | PubMed |
| 26650926 | BACKGROUND | PubMed |
| 27692800 | BACKGROUND | PubMed |
| 28855400 | BACKGROUND | PubMed |
| 29016679 | BACKGROUND | PubMed |
| 29914035 | BACKGROUND | PubMed |
| 30091648 | BACKGROUND | PubMed |
| 30540774 | BACKGROUND | PubMed |
| 31027873 | BACKGROUND | PubMed |
| 32699974 | BACKGROUND | PubMed |
| 32709961 | BACKGROUND | PubMed |
| 33103819 | BACKGROUND | PubMed |
| 37759805 | BACKGROUND | PubMed |
| 38501109 | BACKGROUND | PubMed |
| 38902275 | BACKGROUND | PubMed |
| 39708829 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Picture Naming Test | Other outcome | ConductCognition |
| Short Story Recall | Other outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
| Trail Making Test A | Other outcome | ConductCognition |
| Trail Making Test B | Other outcome | ConductCognition |
| Verbal Learning | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)